Regulatory milestones

Algeta ASA (OSE:ALGETA) added NOK3.40 to NOK244.40 on Friday after EMA's CHMP recommended approval of Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The product is partnered with Bayer AG (Xetra:BAYN). Xofigo is approved for the indication in the U.S., where the companies co-promote it. Algeta was up NOK3.40 for the week.